PTEN germline mutations in patients initially tested for other hereditary cancer syndromes: Would use of risk assessment tools reduce genetic testing?

Oncologist

Volumn 18, Issue 10, 2013, Pages 1083-1090

  Mester, Jessica L ^a,b   Moore, Rebekah A ^a,c   Eng, Charis ^a,b,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cowden syndrome; Genetic testing; Hereditary cancer syndromes; PTEN hamartoma tumor syndrome; Risk assessment

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PTEN PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE INHERITANCE; DIFFERENTIAL DIAGNOSIS; FAMILIAL CANCER; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC RISK; GENETIC SCREENING; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; BREAST NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; COLORECTAL TUMOR; COST BENEFIT ANALYSIS; ENDOMETRIAL NEOPLASMS; GENETICS; GERMLINE MUTATION; HAMARTOMA SYNDROME, MULTIPLE; PATHOLOGY;

ADULT; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; COST-BENEFIT ANALYSIS; DIAGNOSIS, DIFFERENTIAL; ENDOMETRIAL NEOPLASMS; FEMALE; GENETIC TESTING; GERM-LINE MUTATION; HAMARTOMA SYNDROME, MULTIPLE; HUMANS; PTEN PHOSPHOHYDROLASE; RISK ASSESSMENT;

EID: 84886057665     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0174     Document Type: Article

References (24)

1. O'Daniel JM, Lee K. Whole-genome and wholeexome sequencing in hereditary cancer: Impact on genetic testing and counseling. Cancer J 2012;18: 287-292.
2. Marsh DJ, Kum JB, Lunetta KL et al. PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum Mol Genet 1999;8:1461-1472.
3. Zbuk KM, Eng C. Cancer phenomics: RET and PTEN as illustrative models. Nat Rev Cancer 2007;7: 35-45.
4. Tan MH, Mester JL, Ngeow J et al. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 2012;18:400-407.
5. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. BreastCancerLinkage Consortium. Am J Hum Genet 1995;56:265-271.
6. Vasen HF, Stormorken A, Menko FH et al. MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: A study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol 2001;19:4074-4080.
7. Aarnio M, Sankila R, Pukkala E et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999;81:214-218.
8. Heald B, Mester J, Rybicki L et al. Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers. Gastroenterology 2010;139:1927-1933.
9. Burt R, Neklason DW. Genetic testing for inherited colon cancer. Gastroenterology 2005;128: 1696-1716.
10. Pilarski R, Eng C. Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome J Med Genet 2004;41:323-326.
11. Tan MH, Mester J, Peterson C et al. A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective sStudy of 3042 probands. AmJHumGenet 2011;88:42-56.
12. Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. AmJHumGenet 1998;62: 145-158.
13. Frank TS, Deffenbaugh AM, Reid JE et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: Analysis of 10,000 individuals. J Clin Oncol 2002;20:1480-1490.
14. Vasen HF, Mecklin JP, KhanPMet al. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 1991;34:424-425.
15. Umar A, Boland CR, Terdiman JP et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynchsyndrome)andmicrosatellite instability. J Natl Cancer Inst 2004;96:261-268.
16. Kastrinos F, Steyerberg EW, Mercado R et al. The PREMM(1,2,6) model predicts risk of MLH1 MSH2, and MSH6 germline mutations based on cancer history history Gastroenterology 2011;140:73-81.
17. Chen S, Wang W, Lee S et al. Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA 2006;296:1479-1487.
18. Myers MF, Chang MH, Jorgensen C et al. Genetic testing for susceptibility to breast and ovarian cancer: Evaluating the impact of a direct-toconsumer marketing campaign on physicians' knowledge and practices. Genet Med 2006;8: 361-370.
19. Burt RW, Barthel JS, Dunn KB et al. NCCN clinical practice guidelines in oncology. Colorectal cancer screening. J Natl Compr Canc Netw 2010;8: 8-61.
20. Schroy PC, 3rd, Lal SK, Wilson S et al. Deficiencies in knowledge and familial risk communication among colorectal adenoma patients. J Clin Gastroenterol 2005;39:298-302.
21. Doerr M, Eng C. Personalised care and the genome. BMJ 2012;344:e3174.
22. Shiovitz S, Everett J, Huang SC et al. Head circumference in the clinical detection ofPTENhamartoma tumor syndrome in a clinic population at highrisk of breast cancer. Breast Cancer Res Treat 2010; 124:459-465.
23. Nagy R, Ganapathi S, Comeras I et al. Frequency of germline PTEN mutations in differentiated thyroid cancer. Thyroid 2011;21:505-510.
24. International Society for Gastrointestinal Hereditary Tumours. Colon cancer gene variant databases. Available at: http://www.insight-group.org/ mutations/. Accessed August 21, 2013.